<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1729">
  <stage>Registered</stage>
  <submitdate>26/10/2007</submitdate>
  <approvaldate>26/10/2007</approvaldate>
  <nctid>NCT00551304</nctid>
  <trial_identification>
    <studytitle>Native Kidney Denervation in Patients With End Stage Renal Disease</studytitle>
    <scientifictitle>Native Kidney Denervation in Patients With End Stage Renal Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TP-020 &amp; TP-039</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Renal Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Ardian Catheter

Treatment: devices: Ardian Catheter


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To provide confirmation that renal denervation in ESRD patients is safe and feasible.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To provide evidence of denervation, indication of physiologic response, and assess device performance.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult &gt;= 18 years of age

          -  end stage renal disease, undergoing concurrent dialysis treatment

          -  poorly controlled blood pressure on at least 2 antihypertensive drugs

          -  agrees to have the study procedure(s) performed and additional procedures and
             evaluations, including interventions and follow up visits

          -  competent and willing to provide written, informed consent to participate in this
             clinical study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  renal arterial abnormalities

          -  myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within
             six (6) months

          -  hemodynamically significant valvular heart disease

          -  implantable cardioverter defibrillator (ICD) or pacemaker

          -  respiratory support.

          -  pregnant, nursing or planning to be pregnant

          -  other</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Cracow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate the utility of renal denervation in the treatment of patients with End Stage
      Renal Disease (ESRD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00551304</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Markus Schlaich, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>